CSM Advisors LLC Sells 65,130 Shares of Abbott Laboratories $ABT

Key Points

• CSM Advisors LLC cut its stake in Abbott Laboratories by 67.3% in Q3, selling 65,130 shares and leaving 31,681 shares valued at about $4.24 million.
• Abbott reported quarterly EPS of $1.50 (in line with estimates) on $11.46 billion in revenue (below the $11.80 billion estimate) and provided Q1 2026 guidance of $1.120–$1.180 EPS and FY 2026 guidance of $5.550–$5.800 EPS.
• Analyst sentiment is mixed but positive overall: MarketBeat shows a consensus rating of "Moderate Buy" with a consensus target price of $136.16, even as several firms trimmed price targets while others issued upgrades.

CSM Advisors LLC lowered its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 67.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,681 shares of the healthcare product maker's stock after selling 65,130 shares during the period. CSM Advisors LLC's holdings in Abbott Laboratories were worth $4,242,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories in the third quarter valued at $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $31,000. Anfield Capital Management LLC increased its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares during the last quarter. Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of recent analyst reports. Leerink Partners lowered their price target on Abbott Laboratories from $136.00 to $119.00 and set a "market perform" rating on the stock in a research report on Friday, January 30th. Weiss Ratings downgraded Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, January 26th. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, November 20th. Freedom Capital raised Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 29th. Finally, Piper Sandler decreased their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an "overweight" rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $136.16.

Abbott Laboratories Stock Performance

ABT opened at $107.99 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The business has a fifty day simple moving average of $114.58 and a 200 day simple moving average of $123.80. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.06. The company has a market capitalization of $187.66 billion, a PE ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts' consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company's revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio is presently 67.74%.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares of the company's stock, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.